Holen Sie sich die Stockscreener-App
15.76
1.68%
0.26
Handel nachbörslich:
15.93
0.17
+1.08%
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha
Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener
Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus
Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener
Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks
Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus
Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan
Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan
Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise
Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conf - GuruFocus
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conferences | SYRE Stock News - GuruFocus
Spyre Therapeutics IBD Pipeline Updates Coming at Major June Healthcare Conferences - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Deutsche Bank AG - Defense World
BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% - Yahoo Finance
First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 12.6% on Earnings Beat - Defense World
Spyre Therapeutics: Q1 Earnings Snapshot - New Haven Register
Spyre Therapeutics Reports Q1 2025 Financial Results - TipRanks
Spyre (SYRE) Advances Clinical Trials with Strong Financial Backing | SYRE Stock News - GuruFocus
Spyre Therapeutics Inc Reports Q1 2025 EPS of -$0.60, Beating Estimates, Amid $44.8 Million Net Loss - GuruFocus
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Position Boosted by Tower Research Capital LLC TRC - The AM Reporter
MetLife Investment Management LLC Has $498,000 Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World
Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq
Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PR Newswire
Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan
Spyre Therapeutics (SYRE) to Release Earnings on Thursday - Defense World
Barclays PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):